Beximco Pharma Discussion Threads

[cockneytrader] 13/11/2017 22:16

25% increase in eps for 1st quarter compared to 1st q 2016!

[firtashia] 07/11/2017 15:50

3800- just a consensus

[penpont] 07/11/2017 13:42

Northland Capital have recently taken over as broker for BXP (from Daniel Stewart if memory serves).
They released a note this morning (available on Research Tree) but unfortunately have not provided forecasts.

'Results and product launch into US
This morning Beximco announced it has commenced the export of Sotalol Hydrochloride (80 mg, 120 mg and 160 mg), a generic version of the cardiovascular drug Betapace, to the US. Following the successful launch of Carvedilol to the US in August 2016, this is the second product from Beximco Pharma to be exported to the US.
According to QuintlesIMS data, the market size for Satalol Hydrochloride (including all strengths) in the US is $23 million.
Yesterday, Beximco also announced its audited results for the 12 month period ended 30 June 2017.
Net sales increased to BDT 15,508.8 million (£147.51 million), registering year-on-year growth of 12.5% (2015-16: BDT 13,785.3 million (£135.7 million))
Export sales registered year-on-year growth of 25.2%
Profit before tax increased 12.8% to BDT 2,891.5 million (£27.50 million), (2015-16: BDT 2,564.3 million, £25.24 million)
Yesterday Beximco’s results demonstrated that the Company continues to see good YoY growth, registering double-digit Sales and PBT expansion. Of note, the Group continues to show strong export growth. Also, today’s announcement demonstrates Beximco’s continued progress in the US market, with the launch of its second product there.'

[3800] 07/11/2017 12:29

thanks for that firtashia doe's stockopedia give individual brokers forecasts or just a consensus number?
3800

[firtashia] 07/11/2017 12:06

3800- Agree about the paucity of forecast info, which I see as a positive. I subscribe to Stockopedia and the FY18 forecasts on there are for EPS of 5.19BDT (down from 5.49BDT for FY17) and FY18 forecast net profit of 2863m BDT (up from 2227m BDT for FY17). Revs are forecast to increase to 20410m BDT (from 15500m in FY17) so thats a very healthy increase. It doesnt look as if they have been updated for quite a while so I am keeping a close eye out to see if they are now updated following yesterdays results.

[3800] 07/11/2017 11:29

I'm just taking a quick look at BXP and cannot find any brokers forecasts the only thing I can find is an article from 5 months ago here hxxps://www.stockopedia.com/content/sif-portfolio-may-review-beximco-pharmaceuticals-amp-xlmedia-190274/ saying that the house broker Daniel Stuart forcasts this years earnings to be 21% less than 2016. Has anyone else access to Forecasts more recent?
3800

[mfhmfh] 07/11/2017 09:44

1st quarter results were on 15th November last year.

[mfhmfh] 07/11/2017 09:43

2nd product launched in the US with hopefully more to come:

'With our growing pipeline for the US, we will focus on increasing our presence in the world's largest pharma market in the coming years.'

[mfhmfh] 06/11/2017 14:57

Positive write up on Stockopedia today

[jovi1] 06/11/2017 14:38

agree about the re-rate differentials between us and eu market and other market but it seems odd that growing company with relatively big turnover can have a PE so low, ever stranger that on the day of the result only 50k share change hands. oh well we must do with a divi of approx. 1p a share for now hopefully this will grow quicker in the future

[chrisgail] 06/11/2017 12:25

It will never be rated the same as an Amercian or European Pharmaceuticals company, but they are now turning out consistent figures, with growth, in my opinion the share should be somewhat higher than they are now.

[mfhmfh] 06/11/2017 12:12

solid results with surely growth to come:

· Received approvals for two ANDAs from the US Food and Drug Administration (US FDA)
· Launched 15 products in the domestic market, four of which were launched for the first time in Bangladesh
· Registered 71 new products in 20 countries
· Entered seven new markets - Panama, Ecuador, Tanzania, Zimbabwe, Mali, Cameron and Guinea Conakri
· Formed the Company's first overseas manufacturing collaboration with the joint venture with BioCare Manufacturing (M) Sdn Bhd based in Malaysia
· Granted a sub-license by Medicine Patent Pool of the UN to produce Bristol-Myers Squibb's new hepatitis C drug Daclatasvir



· Net sales increased to BDT 15,508.8 million (£147.51 million), registering year-on-year growth of 12.5% (2015-16: BDT 13,785.3 million (£135.7 million))
o Export sales registered year-on-year growth of 25.2%
· Profit before tax increased 12.8% to BDT 2,891.5 million (£27.50 million), (2015-16: BDT 2,564.3 million, £25.24 million)



All IMHO.

[firtashia] 06/11/2017 11:36

FY results out this morning - happy to hold, will be interested to see in which direction forecast fy18 earnings will be revised.

[rogash] 30/10/2017 11:38

Compared to the previous 18 month period eps are up 17% over this 12 month period.

[cb7] 30/10/2017 10:06

But some figures were given in the announcement. EPS is 5.49BDT for the year. This is disappointing as it shows no growth at all over the 1st half, which was 2.74. The situation is considerably worse if you convert to GBP due to currency changes. Now I know currency fluctuation is out of the control of management, but earnings growth per share in BDT is not.

[firtashia] 26/10/2017 17:29

On the day they announce when the results are going to be announced by, the share price drops, presumably because people dont want to be holding when the results are issued, and for no reason related to the actual performance of the business.

[mfhmfh] 12/10/2017 11:35

large volume today

[outsizeclothes.com] 09/10/2017 10:22

From a commercial point of view this looks to be a potentially very exciting acquisition. It should open up a whole new customer base for cross-selling, especially internationally. I wonder if any of Nuvista's facilities are EU / FDA approved ?

[kenmitch] 07/10/2017 15:59

Agree. The shares to avoid are the ones with hundreds of mostly rubbish posts on ADVFN every day. Was originally attracted to BXP by then very high Stockopedia ratings, since when the share price has nearly doubled.

[mfhmfh] 07/10/2017 11:21

happy to be in a 'quiet share'.

[kenmitch] 07/10/2017 09:38

Yes. Share price reaction muted, probably because BXP off most investors radar.

[mfhmfh] 06/10/2017 08:50

positive news today

[outsizeclothes.com] 29/9/2017 15:40

Perhaps Beximco aren't totally sure of just how good their distribution agents, and accordingly their sales people, are ?
Better to check that out with smaller value/market size products first, to see if sales are generated, and how quickly. This before committing to supply large amounts of more valuable stock with perhaps a shorter shelf-life, which might, or might not, sell.

[zcaprd7] 29/9/2017 15:15

Are they fiddling around the edges of the smaller markets, to demonstrate to the authorities their competence?You are correct about the release numbers, but so little context, and zero feel for the future strategy...